Who is sponsoring NCT03628443?

NCT03628443 is sponsored by Coney Island Hospital, Brooklyn, NY.

What drugs are being tested in NCT03628443?

Interventions in NCT03628443: Fibroblast Growth Factor 23.

What condition does NCT03628443 study?

NCT03628443 studies Cardio-Renal Syndrome, Heart Failure, Chronic Kidney Diseases.

Is NCT03628443 still recruiting?

NCT03628443 is currently status unknown. Last updated 16 October 2018.

Last reviewed 2018-10-16 · How we verify

NCT03628443: CRiSPS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cardiorenal Risk Stratification Pilot Study

Status unknown Last updated 16 October 2018

What this trial tests

trial testing Fibroblast Growth Factor 23 in Cardio-Renal Syndrome in 100 participants. Status unknown.

Timeline

19 July 2018

Primary endpoint
31 October 2019

31 December 2019

Quick facts

Lead sponsor	Coney Island Hospital, Brooklyn, NY
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	19 July 2018
Primary completion	31 October 2019
Estimated completion	31 December 2019
Sites	1 location across United States

Drugs / interventions tested

Fibroblast Growth Factor 23

Conditions studied

Cardio-Renal Syndrome — all drugs for Cardio-Renal Syndrome →
Heart Failure — all drugs for Heart Failure →
Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →

Sponsor

Coney Island Hospital, Brooklyn, NY

Who can join

18 and older, any sex, with Cardio-Renal Syndrome or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is prospective cohort study with the purpose of improving our understanding of morbidity and mortality risk in patients with heart failure and chronic kidney disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardio-Renal Syndrome

Currently open trials in the same condition.

NCT07008365 — The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure · Phase 3 · recruiting
NCT06521801 — Cardio-Renal Registry · recruiting
NCT04170855 — Kidney Sodium Content in Cardiorenal Patients · NA · recruiting

Other Coney Island Hospital, Brooklyn, NY trials

Trials by the same sponsor.

NCT03707626 — Collateral Circulation to LAD and Wellens Sign · unknown
NCT03627884 — Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter L · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03628443 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Coney Island Hospital, Brooklyn, NY
Last refreshed: 16 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03628443.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing